Gastroesophageal reflux disease and one anastomosis gastric bypass

Abstract

This review examines the incidence, diagnosis, and management of gastroesophageal reflux disease (GERD) following one anastomosis gastric bypass (OAGB), a notable concern in bariatric surgery outcomes. Through a literature review from 2010 to 2024, utilizing databases such as PubMed, Embase, and the Cochrane Library, this study collects evidence from both large scale and smaller studies that report on acid reflux post-OAGB. The aim is to provide a comprehensive overview of GERD occurrence, diagnostic methodologies, and treatment options postsurgery. The findings reveal a varied incidence rate of GERD post-OAGB, from as minimal as 0.17% to a peak of 4.1%. Diagnostic practices differ, with bile reflux predominantly identified, alongside instances of acid reflux. Management strategies primarily involve proton-pump inhibitors (PPIs), with recommended treatment durations ranging from 3 to 12 months, favoring a 6-month regimen. The study validates the importance of customizing treatment durations based on individual patient profiles and the potential implications of extended PPI use. Surgical intervention remains a last resort, reserved for severe GERD cases unresponsive to medical treatment or when significant pathological changes are evident.